



ASX & MEDIA RELEASE

11 NOVEMBER 2019

CANNABIS OCTOBER UPDATE – RECORD INCOME ACHIEVED

- **Record month** for number of **cannabis bottles** (NanaBis™ and NanaBidual™) dispensed in October 2019 of 846 bottles.
- **Record month** for **revenue achieved** for cannabis in October 2019 .
- **Last patient** in Royal North Shore Hospital (RNSH) Trial recruited and in intervention stage.
- **735 bottles** of NanaBis™ dispensed – an **increase of 43%** over the previous best month.
- **65% Quarterly Revenue growth** over previous rolling quarter achieved in NanaBis™.
- **93 Doctors and 161 patients** enrolled in recently commenced Observational Study.

Medlab Clinical Ltd (ASX: MDC) is pleased to announce that it has achieved a record month in cannabis revenue with 846 bottles dispensed.

NanaBis™, Medlab's lead pain drug candidate programme using standardised, purified THC and CBD in Medlab's proprietary NanoCelle™ delivery platform has seen unprecedented increases in demand. Sales are via the governments Special Access Scheme and demand increase in part reflects 2 emerging factors differentiating Medlab products:

1. NanaBis status with clinical trials at Royal North Shore Hospital
2. More recently allowing doctors and patients to participate via the TGA approved Observational Study designed in collaboration with US FDA. Interest in the Study has been high and currently 93 Doctors and 161 patients have enrolled.

This increase in demand required a rescaling of-the production process. Medlab currently has some 4,000 units of NanaBis™ in production to meet its short term needs.

NanaBis™ continues to achieve very positive results through its prescription via the SAS, and Observational Study. Recent case studies have reported:

- Significant reduction in medications taken (in particularly opioids)
- Significant improvements in quality of life:
 - Improved sleep
 - Increase in appetite
 - Decrease in anxiety
 - Pain reduction

A summary of 3 individual case studies from 3 different Doctors are summarised below:

	Patient 1	Patient 2	Patient 3
Age	29	28	65
Gender	F	M	F
Condition	Pain associated with cancer	Pain associated with cancer	Neuropathic pain
Medication(s) pre NanaBis™	<ul style="list-style-type: none"> • Endone • Valium • Ondansetron • Tramadol 	<ul style="list-style-type: none"> • MS Contin • Endep • Lyrica • Endone • Panadol 	<ul style="list-style-type: none"> • Oxycontin • Endone
Medications post NanaBis™	Ceased all other medications	Reduced MS Contin dosing by half after a few days	Significant reduction in Endone to sometimes none at all
Symptoms	Pain score reduced from 9/10 to 2/10 (low as 1/10). Appetite has increased, nausea has subsided and has improved sleep.	Significant pain relief after a few days and now has no pain at all and now able to walk freely without crutches.	Patient reports better quality of life through better sleep, reduced pain, being able to socialise more easily and reduced anxiety.

Medlab’s CEO, Dr Sean Hall said “Medlab prioritises Trial patient access over SAS uses to which as an update, the RNSH Trial has recruited its last patient and is currently in the intervention stage with again early data received is very encouraging. Medlab is very excited with the progress of results from NanaBis™ as the Company moves forward to drug registration.”

ISSUED FOR: MEDLAB CLINICAL LTD (ASX: MDC) – www.medlab.co

FOR FURTHER INFORMATION: DR SEAN HALL, CEO, MEDLAB CLINICAL
TEL: +61 2 8203 9520, sean_hall@medlab.co

ABOUT MEDLAB – www.medlab.co

Medlab Clinical is an Australian based medical life science company, developing therapeutic pathways for diagnosed chronic diseases. It is advanced in developing therapies for pain management, depression and obesity as well as earning revenue from sale of nutritional products in Australia and the United States. In pain management Medlab is developing cannabis-based medicines. The Medlab developed nano-particle medicine delivery system, NanoCelle™, is being applied to its medicines, nutritional products and off-patent drugs like statins. Medlab has a growing patent portfolio.